BACKGROUND AND PURPOSE: Longitudinal MR imaging measures provide an opportunity to track progression in HD before the emergence of clinical symptoms. This may prove useful in assessing disease-modifying treatments. We investigated how caudate and global volumes change as HD progresses from premanifest to early disease. MATERIALS AND METHODS: Forty HD gene-positive individuals and 19 controls underwent serial volumetric MR imaging (baseline, 12 and 27 months; 2 or 3 scans per person). At baseline, 3 patients with HD were premanifest but developed overt motor features during the study, and 37 had early HD. All had dates of motor onset recorded. Caudates, lateral ventricles, and TIVs were measured using semiautomated procedures. Linear mixed models were used to investigate differences between HD and controls in relation to motor onset, controlling for TIV, sex, and age. RESULTS: Extrapolating backwards in time, we found that differences in caudate and ventricular volumes between patients with HD and controls were evident 14 and 5 years, respectively, before motor onset (P < .05). At onset, caudate volume was 2.58 mL smaller than that in controls (P < .0001); ventricular volume was 9.27 mL larger (P < .0001). HD caudate atrophy rates were linear, showed low variability between subjects, and were approximately 10-fold higher than those in controls (P < .001). HD ventricular enlargement rates were variable between subjects, were approximately 4-fold higher than those in controls at onset (P < .001), and accelerated with disease duration (P = .02). CONCLUSIONS: We provide evidence of acceleration of global atrophy in HD with disproportionate caudate involvement. Both caudate and global measures may be of use as early markers of HD pathology.
BACKGROUND AND PURPOSE: Longitudinal MR imaging measures provide an opportunity to track progression in HD before the emergence of clinical symptoms. This may prove useful in assessing disease-modifying treatments. We investigated how caudate and global volumes change as HD progresses from premanifest to early disease. MATERIALS AND METHODS: Forty HD gene-positive individuals and 19 controls underwent serial volumetric MR imaging (baseline, 12 and 27 months; 2 or 3 scans per person). At baseline, 3 patients with HD were premanifest but developed overt motor features during the study, and 37 had early HD. All had dates of motor onset recorded. Caudates, lateral ventricles, and TIVs were measured using semiautomated procedures. Linear mixed models were used to investigate differences between HD and controls in relation to motor onset, controlling for TIV, sex, and age. RESULTS: Extrapolating backwards in time, we found that differences in caudate and ventricular volumes between patients with HD and controls were evident 14 and 5 years, respectively, before motor onset (P < .05). At onset, caudate volume was 2.58 mL smaller than that in controls (P < .0001); ventricular volume was 9.27 mL larger (P < .0001). HD caudate atrophy rates were linear, showed low variability between subjects, and were approximately 10-fold higher than those in controls (P < .001). HD ventricular enlargement rates were variable between subjects, were approximately 4-fold higher than those in controls at onset (P < .001), and accelerated with disease duration (P = .02). CONCLUSIONS: We provide evidence of acceleration of global atrophy in HD with disproportionate caudate involvement. Both caudate and global measures may be of use as early markers of HD pathology.
Authors: H Diana Rosas; David H Salat; Stephanie Y Lee; Alexandra K Zaleta; Vasanth Pappu; Bruce Fischl; Doug Greve; Nathanael Hevelone; Steven M Hersch Journal: Brain Date: 2008-03-12 Impact factor: 13.501
Authors: Susie M D Henley; Edward J Wild; Nicola Z Hobbs; Jason D Warren; Chris Frost; Rachael I Scahill; Gerard R Ridgway; David G MacManus; Roger A Barker; Nick C Fox; Sarah J Tabrizi Journal: Neuropsychologia Date: 2008-03-06 Impact factor: 3.139
Authors: Jane S Paulsen; Michael Hayden; Julie C Stout; Douglas R Langbehn; Elizabeth Aylward; Christopher A Ross; Mark Guttman; Martha Nance; Karl Kieburtz; David Oakes; Ira Shoulson; Elise Kayson; Shannon Johnson; Elizabeth Penziner Journal: Arch Neurol Date: 2006-06
Authors: Andrea Ciarmiello; Milena Cannella; Secondo Lastoria; Maria Simonelli; Luigi Frati; David C Rubinsztein; Ferdinando Squitieri Journal: J Nucl Med Date: 2006-02 Impact factor: 10.057
Authors: E H Aylward; B F Sparks; K M Field; V Yallapragada; B D Shpritz; A Rosenblatt; J Brandt; L M Gourley; K Liang; H Zhou; R L Margolis; C A Ross Journal: Neurology Date: 2004-07-13 Impact factor: 9.910
Authors: Susie M D Henley; Edward J Wild; Nicola Z Hobbs; Chris Frost; David G MacManus; Roger A Barker; Nick C Fox; Sarah J Tabrizi Journal: Mov Disord Date: 2009-04-30 Impact factor: 10.338
Authors: Aaron C Rising; Jia Xu; Aaron Carlson; Vincent V Napoli; Eileen M Denovan-Wright; Ronald J Mandel Journal: Exp Neurol Date: 2010-12-28 Impact factor: 5.330
Authors: F Sampedro; S Martínez-Horta; J Perez-Perez; A Horta-Barba; J Martin-Lahoz; A Alonso-Solís; I Corripio; B Gomez-Anson; J Kulisevsky Journal: AJNR Am J Neuroradiol Date: 2019-09 Impact factor: 3.825
Authors: Zhihong Guo; Gay Rudow; Olga Pletnikova; Kari-Elise Codispoti; Brent A Orr; Barbara J Crain; Wenzhen Duan; Russell L Margolis; Adam Rosenblatt; Christopher A Ross; Juan C Troncoso Journal: Mov Disord Date: 2012-09-13 Impact factor: 10.338
Authors: Elizabeth H Aylward; Deborah L Harrington; James A Mills; Peggy C Nopoulos; Christopher A Ross; Jeffrey D Long; Dawei Liu; Holly K Westervelt; Jane S Paulsen Journal: J Huntingtons Dis Date: 2013
Authors: Dustin K Ragan; Jonathon Cerqua; Tiffany Nash; Robert C McKinstry; Joshua S Shimony; Blaise V Jones; Francesco T Mangano; Scott K Holland; Weihong Yuan; David D Limbrick Journal: J Neurosurg Pediatr Date: 2015-03-06 Impact factor: 2.375
Authors: Aaron Bonner-Jackson; Jeffrey D Long; Holly Westervelt; Geoffrey Tremont; Elizabeth Aylward; Jane S Paulsen Journal: J Int Neuropsychol Soc Date: 2013-05-23 Impact factor: 2.892